# A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease

> **NCT06225973** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Telios Pharma, Inc.** · enrollment: 880 (estimated)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** TL-925
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06225973
- **Lead sponsor:** Telios Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-06
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 880 (ESTIMATED)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06225973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06225973, "A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06225973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*